Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTM2 | P28161 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | BCL6 | P41182 | 1/20 | 0.46 |
| ▸ | BCOR | Q6W2J9 | 1/20 | 0.46 |
| ▸ | SIRT5 | Q9NXA8 | 2/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8200406 | 0.90 | ALDH1A1 (0.55) | ALDH1A1MAPTKAT2BTDP1ATM | |
| SCHEMBL8196345 | 0.85 | SIRT5 (0.55) | MAPTKAT2BTDP1ATMSIRT5 | |
| SCHEMBL8336041 | 0.84 | ALDH1A1 (0.56) | GSTM2ALDH1A1MAPTKAT2BTDP1 | |
| SCHEMBL1283854 | 0.84 | MAPT (0.54) | ALDH1A1MAPTKAT2BTDP1ATM | |
| SCHEMBL14155094 | 0.83 | GSTM2 (0.54) | GSTM2ALDH1A1MAPTKAT2BTDP1 | |
| SCHEMBL1420919 | 0.82 | LMNA (0.56) | ALDH1A1MAPTKAT2BTDP1ATM | |
| SCHEMBL17845498 | 0.82 | ATM (0.51) | ALDH1A1MAPTKAT2BTDP1ATM | |
| SCHEMBL30532042 | 0.82 | ATM (0.51) | ALDH1A1MAPTKAT2BTDP1ATM | |
| SCHEMBL3515437 | 0.81 | HCAR3 (0.52) | ALDH1A1MAPTKAT2BTDP1ATM | |
| SCHEMBL7745956 | 0.81 | LMNA (0.57) | ALDH1A1MAPTKAT2BTDP1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | SOLVAY PHARMECEUTICALS B.V. (NL) | 2007-03-29 | — | — | US | disclosed |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | SOLVAY PHARMACEUTICALS B.V. | 2006-06-08 | — | — | US | disclosed |
| US-6121264-A | GLUTAMATE RECEPTOR ANTAGONIST, AMPA RECEPTOR ANTAGONIST, NMDA-GLYCINE RECEPTOR ANTAGONIST, KAINIC ACID NEUROTOXICITY INHIBITOR, ANTIISCHEMIC AGENT, PSYCHOTROPIC AGENT | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2000-09-19 | — | — | US | disclosed |
| EP-0919554-A1 | IMIDAZOLE-SUBSTITUTED QUINOXALINEDIONE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1999-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072870-A2 | PHENYLPIPERAZINE DERIVATIVES WITH A COMBINATION OF PARTIAL DOPAMINE-D2 RECEPTOR AGONISM AND SEROTONIN REUPTAKE INHIBITION | HTR2C, HTR2A, HTR5A | GSTM2 1222/4885ALDH1A1 1420/4885MAPT 755/4885 |
| US-20060122189-A1 | Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition | HTR2C, HTR2A, HTR5A | GSTM2 1222/4885ALDH1A1 1420/4885MAPT 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.